.jpg)
.png)
All
As a professional organization, the National Lipid Association's mission has been to reduce the morbidity and mortality from cardiovascular disease by increasing the understanding of the pathophysiology, and detection and optimal treatment of lipid disorders. Developing patient... more
Hypertension, High Serum Total Cholesterol, and Diabetes: Racial and Ethnic Prevalence Differences in U.S. Adults, 1999–2006
Jointly Sponsored Session with National Lipid Association and European Atherosclerosis Society From the NLA 2024 Scientific Sessions in Las Vegas, NV This session was provided with educational grant support from Amgen and Esperion
Regeneron Pharmaceuticals, Inc. today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH). more
Join the Genetics Work Group! The functions of the Cardiometabolic Work Group include: The section will be asked to propose topics and speakers for meetings Raise awareness among the membership and potential NLA members about the section... more
Committees of the NLA Executive Committee The following committees will report to the Executive Committee: Executive Committee The Executive Committee, consisting of the officers of the NLA, shall act on behalf of the Board of... more
Introduction Elevated cholesterol is a well-known and modifiable risk factor for cardiovascular disease. Hyperlipidemia due to secondary causes is common and should be evaluated as part of treatment. Potential secondary causes include diabetes mellitus, excessive alcohol intake, cholestatic... more
Medical literature is replete with the use of more complex statistics these days, and many of our practice guidelines require more and more rigorously conducted studies with sophisticated statistics to be considered. It is important that clinical lipid specialists and others in the field of... more